Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

Bromelain topical - MediWound

Drug Profile

Bromelain topical - MediWound

Alternative Names: Debrase; Debrase Gel Dressing; KMW-1; NexoBrid; NexoBridN

Latest Information Update: 10 Oct 2019

Price : $50 *
  • Adis is an information provider. We do not sell or distribute actual drugs.
  • Final gross price and currency may vary according to local VAT and billing address.
  • Your purchase entitles you to full access to the information contained in our drug profile at the time of purchase.
  • A link to download a PDF version of the drug profile will be included in your email receipt.

At a glance

  • Originator MediWound
  • Developer MediWound; Teva Pharmaceutical Industries; Tuteur
  • Class Anti-inflammatories; Cysteine endopeptidases; Skin disorder therapies
  • Mechanism of Action Peptide hydrolase replacements
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    Yes - Burns
  • New Molecular Entity No

Highest Development Phases

  • Marketed Burns
  • Preclinical Wounds

Most Recent Events

  • 06 Aug 2019 MediWound announces intention to submit BLA to the US FDA for Burns in Q2 2020
  • 01 Aug 2019 MediWound initiates an expanded-access programme for Acute deep partial and full thickness burn injuries in USA (NCT04040660)
  • 31 Jul 2019 MediWound and Vericel completes a pre-BLA meeting with the FDA to discuss the regulatory pathway for bromelain topical
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top